Samarth Kulkarni - Feb 18, 2023 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role: Chief Executive Officer, Director
Signature: /s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol: CRSP
Transactions as of: Feb 18, 2023
Transactions value $: -$307,561
Form type: 4
Date filed: 2/22/2023, 04:38 PM
Previous filing: Jan 31, 2023
Next filing: Mar 1, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRSP	Common Shares	Options Exercise		+13.3K	+3.59%		382K	Feb 18, 2023	Direct	F1
transaction	CRSP	Common Shares	Tax liability	-$308K	-6.37K	-1.67%	$48.26	376K	Feb 21, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRSP	Restricted Stock Units	Options Exercise		-13.3K	-25%		39.8K	Feb 18, 2023	Common Shares	13.3K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2	Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3	This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.